DPYD Antibodies

Santa Cruz Biotechnology delivers a wide array of DPYD monoclonal antibodies for investigating dihydropyrimidine dehydrogenase (DPD) in cellular processes. DPYD Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Dihydropyrimidine dehydrogenase is a key enzyme in the pyrimidine catabolic pathway, responsible for the metabolism of uracil and thymine. DPD activity is crucial for maintaining nucleotide balance and cellular homeostasis, while alterations in DPD function can significantly impact drug metabolism and cancer therapy. Understanding DPD expression and regulation advances therapeutic strategies, particularly in fluoropyrimidine-based chemotherapy research. DPYD monoclonal antibodies enable detailed analysis of protein localization, expression patterns, and molecular interactions. Researchers can utilize multiple formats, including antibodies conjugated to horseradish peroxidase (HRP), phycoerythrin (PE), and fluorescein isothiocyanate (FITC). Santa Cruz Biotechnology monoclonal antibodies support breakthrough discoveries in cancer research and therapeutic development, advancing scientific understanding of DPD's role in human health.